The Lancet Respiratory Medicine, ISSN 2213-2600, 11/2019, Volume 7, Issue 11, pp. 951 - 963
Since the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune...
MORTALITY | MULTICENTER | METAANALYSIS | RESPIRATORY SYSTEM | CORRELATE | CRITICAL CARE MEDICINE
MORTALITY | MULTICENTER | METAANALYSIS | RESPIRATORY SYSTEM | CORRELATE | CRITICAL CARE MEDICINE
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 09/2019, Volume 220, Issue 8, pp. 1325 - 1334
Abstract The impact of variation in host genetics on replication of human immunodeficiency virus type 1 (HIV-1) in demographically diverse populations remains...
HIV-1 | INFECTIOUS DISEASES | GWAS | DETERMINANTS | host genetics | AIDS | MICROBIOLOGY | IMMUNOLOGY | GENETIC RESTRICTION | ADVANTAGE | INDIVIDUALS | viral load | genome-wide association study | CHEMOKINE RECEPTOR | RESISTANCE | HLA | HIV-1 INFECTION | EXPRESSION | DISEASE PROGRESSION
HIV-1 | INFECTIOUS DISEASES | GWAS | DETERMINANTS | host genetics | AIDS | MICROBIOLOGY | IMMUNOLOGY | GENETIC RESTRICTION | ADVANTAGE | INDIVIDUALS | viral load | genome-wide association study | CHEMOKINE RECEPTOR | RESISTANCE | HLA | HIV-1 INFECTION | EXPRESSION | DISEASE PROGRESSION
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 07/2019
Abstract Background Duration of viral shedding is a determinant of infectivity and transmissibility, but few data exist about oseltamivir's ability to alter...
Journal Article
The Journal of infectious diseases, 06/2019
The impact of variation in host genetics on replication of HIV-1 in demographically diverse populations remains uncertain. Here, we perform a genome-wide...
Journal Article
AIDS, ISSN 0269-9370, 04/2019, Volume 33, Issue 5, pp. 845 - 853
BACKGROUND:HIV-exposed-uninfected (HEU) infants have increased infectious morbidity and mortality; little is known about their levels of inflammation and...
INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | immune activation | ENDOTHELIAL ACTIVATION | IMMUNOLOGY | MITOCHONDRIAL-DNA | ANTIRETROVIRAL EXPOSURE | VIROLOGY | HIV-exposed-uninfected infants | inflammation | CHILDREN BORN | growth | INFECTED PATIENTS | morbidity | MICROBIAL TRANSLOCATION | oxidative stress | T-LYMPHOCYTES | D-DIMER | Mother and child | Antiviral agents | Patient outcomes | Analysis | Dosage and administration | Infants | HIV infection | Health aspects | Risk factors
INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | immune activation | ENDOTHELIAL ACTIVATION | IMMUNOLOGY | MITOCHONDRIAL-DNA | ANTIRETROVIRAL EXPOSURE | VIROLOGY | HIV-exposed-uninfected infants | inflammation | CHILDREN BORN | growth | INFECTED PATIENTS | morbidity | MICROBIAL TRANSLOCATION | oxidative stress | T-LYMPHOCYTES | D-DIMER | Mother and child | Antiviral agents | Patient outcomes | Analysis | Dosage and administration | Infants | HIV infection | Health aspects | Risk factors
Journal Article
The Lancet Infectious Diseases, ISSN 1473-3099, 03/2019, Volume 19, Issue 3, pp. 253 - 264
Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of...
ABACAVIR | LAMIVUDINE | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | DOUBLE-BLIND | 2ND-LINE ANTIRETROVIRAL THERAPY | NAIVE ADULTS | Highly active antiretroviral therapy | Analysis | Lopinavir | Nucleosides | DNA polymerases | Adults | Product development | HIV (Viruses) | Health aspects | Health care | Slopes | Drugs | Therapy | RNA-directed DNA polymerase | Gastrointestinal tract diseases | Ritonavir | Clinical trials | Infections | Drug resistance | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Safety | Drug therapy | Active control | Failure | Public health | Antiretroviral drugs | Anemia | Diarrhea | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | Studies | Lower bounds | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Algorithms | Mutation
ABACAVIR | LAMIVUDINE | INFECTIOUS DISEASES | ONCE-DAILY DOLUTEGRAVIR | RALTEGRAVIR | DOUBLE-BLIND | 2ND-LINE ANTIRETROVIRAL THERAPY | NAIVE ADULTS | Highly active antiretroviral therapy | Analysis | Lopinavir | Nucleosides | DNA polymerases | Adults | Product development | HIV (Viruses) | Health aspects | Health care | Slopes | Drugs | Therapy | RNA-directed DNA polymerase | Gastrointestinal tract diseases | Ritonavir | Clinical trials | Infections | Drug resistance | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Safety | Drug therapy | Active control | Failure | Public health | Antiretroviral drugs | Anemia | Diarrhea | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | Studies | Lower bounds | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Algorithms | Mutation
Journal Article
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the...
ABACAVIR | MEDICINE, GENERAL & INTERNAL | THERAPY | ONCE-DAILY DOLUTEGRAVIR | SAFETY | OPEN-LABEL | INHIBITORS | TENOFOVIR/EMTRICITABINE | RITONAVIR | Anti-Retroviral Agents - therapeutic use | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV-1 - isolation & purification | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Clinical trials | Antiviral agents | HIV (Viruses) | Analysis | Anti-HIV agents | Health care | Emtricitabine | Antiretroviral drugs | Therapy | Tablets | Toxicity | Lamivudine | Infections | Exposure | Ribonucleic acid--RNA | Drug resistance | Antiretroviral therapy | Tenofovir | Randomization | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Safety | Drug therapy
ABACAVIR | MEDICINE, GENERAL & INTERNAL | THERAPY | ONCE-DAILY DOLUTEGRAVIR | SAFETY | OPEN-LABEL | INHIBITORS | TENOFOVIR/EMTRICITABINE | RITONAVIR | Anti-Retroviral Agents - therapeutic use | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Humans | Middle Aged | Anti-Retroviral Agents - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV-1 - isolation & purification | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Viral Load - drug effects | Clinical trials | Antiviral agents | HIV (Viruses) | Analysis | Anti-HIV agents | Health care | Emtricitabine | Antiretroviral drugs | Therapy | Tablets | Toxicity | Lamivudine | Infections | Exposure | Ribonucleic acid--RNA | Drug resistance | Antiretroviral therapy | Tenofovir | Randomization | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Safety | Drug therapy
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 04/2018, Volume 18, Issue 1, pp. 191 - 11
Background: Efavirenz-based antiretroviral therapy (ART) regimens are preferred for treatment of adult HIV-positive patients co-infected with tuberculosis...
ART | Tuberculosis | HIV | Eastern Europe | Efavirenz | Outcomes | Protease inhibitor | MORTALITY | INFECTIOUS DISEASES | INITIATION | SAFETY | RIFAMPICIN | PREVALENCE | INFECTED ADULTS | START | RIFABUTIN | Europe, Eastern | Anti-Retroviral Agents - therapeutic use | Prospective Studies | Europe | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Tuberculosis - complications | Male | Survival Rate | Treatment Outcome | Benzoxazines - therapeutic use | Latin America | Tuberculosis - drug therapy | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | HIV Infections - mortality | Antitubercular Agents - therapeutic use | Complications and side effects | HIV patients | Dosage and administration | Research | Drug therapy | Antiretrovirals | Malalts de sida | Amèrica Llatina | AIDS patients | Europa de l'Est | Antiretroviral agents | Tuberculosi | Europa occidental | Western Europe
ART | Tuberculosis | HIV | Eastern Europe | Efavirenz | Outcomes | Protease inhibitor | MORTALITY | INFECTIOUS DISEASES | INITIATION | SAFETY | RIFAMPICIN | PREVALENCE | INFECTED ADULTS | START | RIFABUTIN | Europe, Eastern | Anti-Retroviral Agents - therapeutic use | Prospective Studies | Europe | Humans | Middle Aged | Risk Factors | Proportional Hazards Models | Tuberculosis - complications | Male | Survival Rate | Treatment Outcome | Benzoxazines - therapeutic use | Latin America | Tuberculosis - drug therapy | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | HIV Infections - mortality | Antitubercular Agents - therapeutic use | Complications and side effects | HIV patients | Dosage and administration | Research | Drug therapy | Antiretrovirals | Malalts de sida | Amèrica Llatina | AIDS patients | Europa de l'Est | Antiretroviral agents | Tuberculosi | Europa occidental | Western Europe
Journal Article
Open Forum Infectious Diseases, ISSN 2328-8957, 11/2018, Volume 5, Issue suppl_1, pp. S392 - S392
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 07/2018, Volume 67, Issue 3, pp. 341 - 349
Abstract Background Early clinical severity assessments during the 2009 influenza A H1N1 pandemic (pH1N1) overestimated clinical severity due to selection bias...
pandemic influenza | severity | case fatality ratio | clinical research | pandemic preparedness | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | A H1N1 VIRUS | 1ST | SURVEILLANCE | INFECTION | FATALITY RISK | and
pandemic influenza | severity | case fatality ratio | clinical research | pandemic preparedness | INFECTIOUS DISEASES | MICROBIOLOGY | IMMUNOLOGY | A H1N1 VIRUS | 1ST | SURVEILLANCE | INFECTION | FATALITY RISK | and
Journal Article
Eurosurveillance, ISSN 1025-496X, 05/2018, Volume 23, Issue 21, pp. 34 - 45
Background: Direct comparisons between countries in core HIV care parameters are often hampered by differences in data collection. Aim: Within the EuroSIDA...
REVERSE-TRANSCRIPTASE INHIBITOR | INFECTIOUS DISEASES | HIV CARE | THERAPY | RITONAVIR PLUS LAMIVUDINE | CASCADE | AIDS | OPEN-LABEL | INFECTION | CONTINUUM | LOPINAVIR | Treatment outcome | Continuity of patient care | Surveillance | HIV infection | Epidemiology | Europe
REVERSE-TRANSCRIPTASE INHIBITOR | INFECTIOUS DISEASES | HIV CARE | THERAPY | RITONAVIR PLUS LAMIVUDINE | CASCADE | AIDS | OPEN-LABEL | INFECTION | CONTINUUM | LOPINAVIR | Treatment outcome | Continuity of patient care | Surveillance | HIV infection | Epidemiology | Europe
Journal Article
HIV Medicine, ISSN 1464-2662, 01/2018, Volume 19, Issue 1, pp. 65 - 71
Objectives The Maraviroc Switch (MARCH) study week 48 data demonstrated that maraviroc, a chemokine receptor‐5 (CCR5) inhibitor, was a safe and effective...
maraviroc | protease inhibitor | HIV‐1 | switch | HIV-1 | INFECTIOUS DISEASES | THERAPY | STATE | HIV Protease Inhibitors - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | CCR5 Receptor Antagonists - administration & dosage | RNA, Viral - blood | Treatment Outcome | Cyclohexanes - administration & dosage | HIV Protease Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Drug-Related Side Effects and Adverse Reactions - epidemiology | Reverse Transcriptase Inhibitors - adverse effects | CCR5 Receptor Antagonists - adverse effects | HIV-1 - isolation & purification | Adult | HIV Infections - drug therapy | Cyclohexanes - adverse effects | Antiretroviral Therapy, Highly Active - methods | Drug Substitution | Silk | Protease inhibitors | Proteases | Analysis | DNA polymerases | T cells | HIV (Viruses) | Antiretroviral drugs | CCR5 protein | Renal function | RNA-directed DNA polymerase | Ritonavir | Durability | Viruses | Lymphocytes T | Triglycerides | Ribonucleic acid--RNA | Cholesterol | CD4 antigen | Confidence intervals | Randomization | Inhibitors | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Clear cell-type renal cell carcinoma | Kidney transplantation
maraviroc | protease inhibitor | HIV‐1 | switch | HIV-1 | INFECTIOUS DISEASES | THERAPY | STATE | HIV Protease Inhibitors - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | CCR5 Receptor Antagonists - administration & dosage | RNA, Viral - blood | Treatment Outcome | Cyclohexanes - administration & dosage | HIV Protease Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Drug-Related Side Effects and Adverse Reactions - epidemiology | Reverse Transcriptase Inhibitors - adverse effects | CCR5 Receptor Antagonists - adverse effects | HIV-1 - isolation & purification | Adult | HIV Infections - drug therapy | Cyclohexanes - adverse effects | Antiretroviral Therapy, Highly Active - methods | Drug Substitution | Silk | Protease inhibitors | Proteases | Analysis | DNA polymerases | T cells | HIV (Viruses) | Antiretroviral drugs | CCR5 protein | Renal function | RNA-directed DNA polymerase | Ritonavir | Durability | Viruses | Lymphocytes T | Triglycerides | Ribonucleic acid--RNA | Cholesterol | CD4 antigen | Confidence intervals | Randomization | Inhibitors | Motivation | Antiretroviral agents | Human immunodeficiency virus--HIV | Adults | Clear cell-type renal cell carcinoma | Kidney transplantation
Journal Article